Transplantation of a bacterial consortium ameliorates trinitrobenzenesulfonic acid-induced colitis and intestinal dysbiosis in rats

Papers of special note have been highlighted as:•• of considerable interest

References

• 1 Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504–1517 (2004).
  MedlineGoogle Scholar
• 2 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434 (2007).
  Medline CASGoogle Scholar
• 3 Machiels K, Joossens M, Sabino J et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275–1283 (2014). •• Shows that differences in gut microbiota exist between ulcerative colitis patients with healthy individuals.
  Medline CASGoogle Scholar
• 4 Gevers D, Kugathasan S, Denson LA et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15, 382–392 (2014).
  Medline CASGoogle Scholar
• 5 Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
  Medline CASGoogle Scholar
• 6 Talley NJ, Abreu MT, Achkar JP et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am. J. Gastroenterol. 106(Suppl. 1), S2–S25 (2011).
  Medline CASGoogle Scholar
• 7 Gionchetti P, Rizzello F, Lammers KM et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J. Gastroenterol. 12, 3306–3313 (2006).
  Medline CASGoogle Scholar
• 8 Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of clostridium difficile infection: a systematic review. J. Clin. Gastroenterol. 48, 693–702 (2014).
  MedlineGoogle Scholar
• 9 Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9, 88–96 (2012).
  CASGoogle Scholar
• 10 van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
  Medline CASGoogle Scholar
• 11 Weingarden AR, Chen C, Bobr A et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver. Physiol. 306, G310–G319 (2014).
  Medline CASGoogle Scholar
• 12 Kunde S, Pham A, Bonczyk S et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J. Pediatr. Gastr. Nutr. 56, 597–601 (2013).
  MedlineGoogle Scholar
• 13 Kao D, Hotte N, Gillevet P, Madsen K. Fecal microbiota transplantation inducing remission in crohn's colitis and the associated changes in fecal microbial profile. J. Clin. Gastroenterol. 48, 625–628 (2014).
  MedlineGoogle Scholar
• 14 Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD – challenges and controversies. Gastroenterology 146, 1554–1563 (2014).
  MedlineGoogle Scholar
• 15 Udayappan SD, Hartstra AV, Dallinga-Thie GM, Nieuwdorp M. Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and Type 2 diabetes mellitus. Clini. Exp. Immunol. 177, 24–29 (2014).
  Medline CASGoogle Scholar
• 16 Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 145, 946–953 (2013).
  MedlineGoogle Scholar
• 17 Moayyedi P, Surette MG, Kim PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109 (2015).
  MedlineGoogle Scholar
• 18 Wei Y, Zhu W, Gong J et al. Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. Gastroenterol. Res. Pract. 2015, 517–597 (2015).
  Google Scholar
• 19 Kump PK, Grochenig HP, Lackner S et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm. Bowel Dis. 19, 2155–2165 (2013). •• Clinical research showed that manipulation of intestinal dysbiosis through fecal microbiota transplantation did not induce remission in patients with ulcerative colitis.
  MedlineGoogle Scholar
• 20 Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108, 1620–1630 (2013).
  Medline CASGoogle Scholar
• 21 Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 55, 1652–1658 (2012).
  MedlineGoogle Scholar
• 22 Lawley TD, Clare S, Walker AW et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing clostridium difficile disease in mice. PLoS Pathog. 8, e1002995 (2012). •• Animal study that shows that a bacterial consortium can resolve Clostridium difficile infection in mice.
  Medline CASGoogle Scholar
• 23 Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1, 1156–1160 (1989).
  Medline CASGoogle Scholar
• 24 Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘repoopulating’ the gut. Microbiome 1, 3 (2013).
  MedlineGoogle Scholar
• 25 Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 146, 1573–1582 (2014).
  MedlineGoogle Scholar
• 26 Hart AL, Hendy P. The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. Proc. Nutr. Soci. 73, 452–456 (2014).
  Medline CASGoogle Scholar
• 27 Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin. Infect. Dis. 60(Suppl. 2), S108–S121 (2015).
  MedlineGoogle Scholar
• 28 Aroniadis OC, Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol. Hepatol. 10(4), 230–237 (2014).
  Google Scholar
• 29 Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease. A systematic review of intervention studies in adult patients. Drugs 72(6), 803–823 (2012).
  MedlineGoogle Scholar
• 30 Li M, Liang P, Li Z et al. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front. Microbiol. 6, 692 (2015). •• Our previous work suggested that bacterial consortium transplantation had comparable effects with fecal microbiota transplantation in re-establishing mucosal barrier functions in mice.
  MedlineGoogle Scholar
• 31 Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96, 795–803 (1989).
  Medline CASGoogle Scholar
• 32 Bobin-Dubigeon C, Collin X, Grimaud N, Robert JM, Le Baut G, Petit JY. Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis. Eur. J. Pharmacol. 431, 103–110 (2001).
  Medline CASGoogle Scholar
• 33 Hamamoto N, Maemura K, Hirata I, Murano M, Sasaki S, Katsu K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin. Exp. Immunol. 117, 462–468 (1999).
  Medline CASGoogle Scholar
• 34 Joossens M, Huys G, Van Steen K et al. High-throughput method for comparative analysis of denaturing gradient gel electrophoresis profiles from human fecal samples reveals significant increases in two bifidobacterial species after inulin-type prebiotic intake. FEMS Microbiol. Ecol. 75, 343–349 (2011).
  Medline CASGoogle Scholar
• 35 Eeckhaut V, Machiels K, Perrier C et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut 62, 1745–1752 (2013).
  Medline CASGoogle Scholar
• 36 Shen J, Zhang B, Wei H et al. Assessment of the modulating effects of fructo-oligosaccarides on fecal microbiota using human flora-associated piglets. Arch. Microbiol. 192, 959–968 (2010).
  Medline CASGoogle Scholar
• 37 Mitsuoka T. Intestinal Bacteria and Health: an Introductory Narrative. Harcourt Brace Jovanovich Japan, Tokyo, Japan (1978).
  Google Scholar
• 38 Tong M, Li X, Wegener Parfrey L et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS ONE 8, e80702 (2013).
  MedlineGoogle Scholar
• 39 He Q, Wang L, Wang F et al. Microbial fingerprinting detects intestinal microbiota dysbiosis in zebrafish models with chemically-induced enterocolitis. BMC Microbiol. 13, 289 (2013).
  MedlineGoogle Scholar
• 40 Gkouskou KK, Deligianni C, Tsatsanis C, Eliopoulos AG. The gut microbiota in mouse models of inflammatory bowel disease. Front. Cell Infect. Microbiol. 4, 28 (2014).
  MedlineGoogle Scholar
• 41 Suskind DL, Brittnacher MJ, Wahbeh G et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active crohn's disease. Inflamm. Bowel Dis. 21, 556–563 (2015).
  MedlineGoogle Scholar
• 42 Huda-Faujan N, Abdulamir AS, Fatimah AB et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem. J. 4, 53–58 (2010).
  Medline CASGoogle Scholar
• 43 Kelly CJ, Zheng L, Campbell EL et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17, 662–671 (2015).
  Medline CASGoogle Scholar
• 44 Bloom SM, Bijanki VN, Nava GM et al. Commensal bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9, 390–403 (2011).
  Medline CASGoogle Scholar
• 45 Lai CC, Cheng A, Huang YT et al. Escherichia fergusonii bacteremia in a diabetic patient with pancreatic cancer. J. Clin. Microbiol. 49, 4001–4002 (2011).
  MedlineGoogle Scholar
• 46 Machiels K, Sabino J, Vandermosten L et al. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut doi:10.1136/gutjnl-2015-309398 (2015) (Epub ahead of print).
  Google Scholar
• 47 Hashash JG, Chintamaneni P, Ramos Rivers CM et al. Patterns of antibiotic exposure and clinical disease activity in inflammatory bowel disease: a 4-year prospective study. Inflamm. Bowel Dis. 21(11), 2576–2582 (2015). •• A prospective study showing that antibiotic exposure amplifies the intestinal dysbiosis in inflammatory bowel disease patients.
  MedlineGoogle Scholar
• 48 Dieleman LA, Goerres MS, Arends A et al. Lactobacillus GG prevents recurrence of colitis in HLA-b27 transgenic rats after antibiotic treatment. Gut 52, 370–376 (2003).
  Medline CASGoogle Scholar
• 49 Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156, 3216–3223 (2010).
  Medline CASGoogle Scholar
• 50 Chang JY, Antonopoulos DA, Kalra A et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435–438 (2008).
  MedlineGoogle Scholar
• 51 Binder HJ. Role of colonic short-chain fatty acid transport in diarrhea. Annu. Rev. Physiol. 72, 297–313 (2010).
  Medline CASGoogle Scholar
• 52 Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4554–4561 (2011).
  Medline CASGoogle Scholar
• 53 Atarashi K, Tanoue T, Oshima K et al. Treg induction by a rationally selected mixture of clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
  Medline CASGoogle Scholar